Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Ozempic, was first approved by the FDA on September 27, 2017, initially for type 2 diabetes management. The medication's remarkable side effect—significant weight loss—transformed its clinical profile and led to the 2021 FDA approval of Wegovy, a higher-dose formulation specifically designed for chronic weight management. Today, patients have multiple pathways to access semaglutide therapy, including brand-name options and compounded alternatives.
When Ozempic Was Approved: The Full Timeline
Ozempic (semaglutide) entered the pharmaceutical market on September 27, 2017, when the FDA granted approval for managing type 2 diabetes in adults. The medication was developed by Novo Nordisk after more than a decade of research into GLP-1 receptor agonists—a class of drugs that mimics a natural hormone controlling blood sugar and appetite. Early clinical trials demonstrated not only blood sugar control but also consistent, clinically meaningful weight reduction across patient populations.
In November 2021, the FDA approved Wegovy, a higher-dose semaglutide injection formulation (2.4 mg weekly) specifically for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This approval validated what many healthcare providers and patients had already observed: semaglutide's weight loss benefits extended far beyond its original diabetes indication. Wegovy's launch accelerated demand across the telehealth and direct-to-patient weight loss market, eventually leading to widespread supply constraints and cost barriers for many patients.
How Semaglutide Works for Weight Loss
Semaglutide functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it binds to GLP-1 receptors throughout the brain and digestive system. When activated, these receptors signal satiety—the feeling of fullness—while simultaneously slowing gastric emptying so food stays in the stomach longer. This dual mechanism reduces hunger signals and decreases overall calorie intake without requiring patients to rely solely on willpower or restriction.
Clinical trials showed that semaglutide users experienced an average weight loss of 15% of baseline body weight over 68 weeks, with some patients achieving 20% or greater reductions. The medication also improves cardiovascular outcomes by reducing blood pressure, lowering cholesterol, and decreasing inflammation markers linked to heart disease. These benefits extend beyond cosmetic concerns—weight loss of 10-15% meaningfully reduces the risk of type 2 diabetes, sleep apnea, joint stress, and certain cancers.
Brand-Name Ozempic vs. Compounded Semaglutide: Key Differences
Ozempic and Wegovy contain identical semaglutide molecules, but differ in approved dosing schedules, labeling, and cost structures. Brand-name Ozempic (for diabetes) typically starts at a lower dose and titrates slowly, while Wegovy (for weight loss) uses a higher therapeutic dose reached over 16 weeks. Both are manufactured through controlled pharmaceutical processes, undergo rigorous quality assurance, and are covered by some insurance plans—though coverage varies widely and may require prior authorization.
PlexusDx partners with licensed 503A compounding pharmacies to provide pharmaceutical-grade semaglutide injections at a flat rate of $149 per month, regardless of dose strength. Compounded semaglutide contains the same active compound as brand products but is formulated in smaller batches under strict pharmacy standards. This approach eliminates insurance requirements, removes membership fees, and offers HSA/FSA eligibility—making GLP-1 therapy accessible to patients regardless of coverage status. Patients can choose the dose that matches their clinical needs without worrying that higher doses will trigger higher bills.
Personalized Semaglutide Therapy: The Role of Genetic Testing
Not every patient responds equally to semaglutide, and genetic variation plays a significant role in treatment outcomes. Key genetic variants in the GLP1R gene (rs6923761), GIPR receptor gene (rs1800437), and appetite-regulation genes like FTO (rs9939609) and MC4R (rs17782313) influence how effectively a patient's body responds to GLP-1 signaling. PlexusDx's Precision Peptide Genetic Test (available as a $99 add-on after the first month) maps 14 peptide-related pathways across 150+ genetic insights to reveal which patients are most likely to achieve dramatic weight loss and metabolic improvement.
Armed with genetic insights, PlexusDx providers can tailor semaglutide therapy to each patient's peptide pathway profile, potentially avoiding months of trial-and-error dosing. Patients with high responder genetics may achieve meaningful results at lower doses, while those with less favorable variants benefit from longer titration schedules or combination approaches. This precision-medicine framework transforms weight loss from a generic protocol into a personalized strategy aligned with each individual's biology.
Access and Affordability: Why Compounded Semaglutide Matters Today
Since Wegovy's 2021 approval, demand for semaglutide far outpaced supply, leading to repeated shortages and price increases that excluded many patients from treatment. Brand-name products often cost $900–$1,400 monthly without insurance coverage, placing GLP-1 therapy out of reach for working-class and middle-income families. Supply chain disruptions, manufacturing constraints, and global demand have kept brand-name options scarce for extended periods, leaving patients frustrated and clinically stuck.
PlexusDx eliminates these barriers by offering compounded semaglutide injections through licensed 503A pharmacies at a flat $149 monthly rate, with no insurance requirement and no membership fees. The service covers all 50 states, integrates telemedicine consultations with licensed clinicians, and accepts HSA/FSA funds for tax-advantaged savings. For patients who have waited months for Ozempic or Wegovy, or who face unaffordable copays despite insurance, compounded semaglutide represents a clinically equivalent alternative that respects both health outcomes and financial reality.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Ozempic (semaglutide 0.5–1 mg weekly) is FDA-approved for type 2 diabetes, while Wegovy (semaglutide 2.4 mg weekly) is specifically approved for chronic weight management. Both contain identical semaglutide, but Wegovy uses higher therapeutic doses for weight loss. PlexusDx compounded semaglutide allows flexible dosing for either indication without insurance barriers.
When did the FDA approve semaglutide for weight loss?
The FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management on November 4, 2021. The drug itself was approved as Ozempic for diabetes on September 27, 2017, but its weight loss benefits weren't formally recognized through a dedicated weight-loss indication until four years later.
How much weight can I expect to lose with semaglutide?
Clinical trials documented average weight loss of approximately 15% of baseline body weight over 68 weeks, with some patients achieving 20% or greater reductions. Results vary based on genetics, adherence, diet, and exercise—which is why PlexusDx offers genetic testing to predict your likely response category before starting therapy.
Is compounded semaglutide as safe as brand-name Ozempic or Wegovy?
Yes. PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies that follow strict FDA standards and quality controls. The active pharmaceutical ingredient is identical to brand products; the difference is manufacturing scale and cost structure, not safety or efficacy.
Can genetic testing predict how well semaglutide will work for me?
Yes. PlexusDx's Precision Peptide Genetic Test analyzes key variants in GLP1R, GIPR, FTO, and MC4R genes that influence semaglutide responsiveness and metabolic outcomes. The $99 test (available after your first month) maps your peptide pathways across 150+ insights to help your clinician personalize your dose and protocol for maximum results.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When is the Best Time to Take Wegovy Injection?
Is Wegovy for Diabetes or Weight Loss?